Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy[S]
Individuals with mixed dyslipidemia, including high triglycerides (TGs) and low high density lipoprotein cholesterol (HDL-C), have increased risk for coronary events. We examined the effect of rare genetic variants in the APOA5 gene region on plasma HDL-C, apolipoprotein A-I (apoA-I), and TG respons...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2013-07-01
|
| Series: | Journal of Lipid Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0022227520421455 |
| _version_ | 1819077189676564480 |
|---|---|
| author | Ariel Brautbar Maja Barbalic Fengju Chen John Belmont Salim S. Virani Steve Scherer Robert A. Hegele Christie M. Ballantyne |
| author_facet | Ariel Brautbar Maja Barbalic Fengju Chen John Belmont Salim S. Virani Steve Scherer Robert A. Hegele Christie M. Ballantyne |
| author_sort | Ariel Brautbar |
| collection | DOAJ |
| description | Individuals with mixed dyslipidemia, including high triglycerides (TGs) and low high density lipoprotein cholesterol (HDL-C), have increased risk for coronary events. We examined the effect of rare genetic variants in the APOA5 gene region on plasma HDL-C, apolipoprotein A-I (apoA-I), and TG response to fenofibric acid monotherapy and in combination with statins. The APOA5 gene region was sequenced in 1,612 individuals with mixed dyslipidemia in a randomized trial of fenofibric acid alone and in combination with statins. Student's t-test and rare variant burden tests were used to examine plasma HDL-C, apoA-I, and TG response. Rare APOA5 promoter region variants were associated with decreased HDL-C and apoA-I levels in response to fenofibric acid therapy; rare missense variants were associated with increased TG response to combination therapy. Further study is needed to examine the effect of these rare variants on coronary outcomes in this population in response to fenofibric acid monotherapy or combined with statins |
| first_indexed | 2024-12-21T18:53:15Z |
| format | Article |
| id | doaj.art-993cfac4bf2842a19c02b3e970eef433 |
| institution | Directory Open Access Journal |
| issn | 0022-2275 |
| language | English |
| last_indexed | 2024-12-21T18:53:15Z |
| publishDate | 2013-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Lipid Research |
| spelling | doaj.art-993cfac4bf2842a19c02b3e970eef4332022-12-21T18:53:41ZengElsevierJournal of Lipid Research0022-22752013-07-0154719801987Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy[S]Ariel Brautbar0Maja Barbalic1Fengju Chen2John Belmont3Salim S. Virani4Steve Scherer5Robert A. Hegele6Christie M. Ballantyne7To whom correspondence should be addressed brautbar@bcm.edu; Center for Human Genetics, Marshfield Clinic Research Foundation, Marshfield, WI; Section of Cardiovascular Research, Department of Molecular and Human Genetics, Houston, TX; Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX; Department of Genetics, Marshfield Clinic, Marshfield, WI; To whom correspondence should be addressed brautbar@bcm.eduHuman Genetics Center, University of Texas Health Science Center, Houston, TXHuman Genetics Center, University of Texas Health Science Center, Houston, TXSection of Cardiovascular Research, Section of Health Services, Houston, TXCenter for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX; Section of Cardiovascular Research, Human Genome Sequencing Center, Houston, TX; Health Policy and Quality Program, Michael E. DeBakey VA Medical Center Health Services Research and Development Center of Excellence, Houston, TX; andSection of Cardiovascular Research, Section of Health Services, Houston, TX; Section of Cardiovascular Research, and Section of Cardiology, Houston, TXRobarts Research Institute, London, Ontario, CanadaSection of Cardiovascular Research, Department of Molecular and Human Genetics, Houston, TX; Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX; Department of Medicine, Baylor College of Medicine, Houston, TXIndividuals with mixed dyslipidemia, including high triglycerides (TGs) and low high density lipoprotein cholesterol (HDL-C), have increased risk for coronary events. We examined the effect of rare genetic variants in the APOA5 gene region on plasma HDL-C, apolipoprotein A-I (apoA-I), and TG response to fenofibric acid monotherapy and in combination with statins. The APOA5 gene region was sequenced in 1,612 individuals with mixed dyslipidemia in a randomized trial of fenofibric acid alone and in combination with statins. Student's t-test and rare variant burden tests were used to examine plasma HDL-C, apoA-I, and TG response. Rare APOA5 promoter region variants were associated with decreased HDL-C and apoA-I levels in response to fenofibric acid therapy; rare missense variants were associated with increased TG response to combination therapy. Further study is needed to examine the effect of these rare variants on coronary outcomes in this population in response to fenofibric acid monotherapy or combined with statinshttp://www.sciencedirect.com/science/article/pii/S0022227520421455apolipoproteinscholesterol-lowering drugslipidsrare variantsfenofibric acidhigh density lipoprotein |
| spellingShingle | Ariel Brautbar Maja Barbalic Fengju Chen John Belmont Salim S. Virani Steve Scherer Robert A. Hegele Christie M. Ballantyne Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy[S] Journal of Lipid Research apolipoproteins cholesterol-lowering drugs lipids rare variants fenofibric acid high density lipoprotein |
| title | Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy[S] |
| title_full | Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy[S] |
| title_fullStr | Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy[S] |
| title_full_unstemmed | Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy[S] |
| title_short | Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy[S] |
| title_sort | rare apoa5 promoter variants associated with paradoxical hdl cholesterol decrease in response to fenofibric acid therapy s |
| topic | apolipoproteins cholesterol-lowering drugs lipids rare variants fenofibric acid high density lipoprotein |
| url | http://www.sciencedirect.com/science/article/pii/S0022227520421455 |
| work_keys_str_mv | AT arielbrautbar rareapoa5promotervariantsassociatedwithparadoxicalhdlcholesteroldecreaseinresponsetofenofibricacidtherapys AT majabarbalic rareapoa5promotervariantsassociatedwithparadoxicalhdlcholesteroldecreaseinresponsetofenofibricacidtherapys AT fengjuchen rareapoa5promotervariantsassociatedwithparadoxicalhdlcholesteroldecreaseinresponsetofenofibricacidtherapys AT johnbelmont rareapoa5promotervariantsassociatedwithparadoxicalhdlcholesteroldecreaseinresponsetofenofibricacidtherapys AT salimsvirani rareapoa5promotervariantsassociatedwithparadoxicalhdlcholesteroldecreaseinresponsetofenofibricacidtherapys AT stevescherer rareapoa5promotervariantsassociatedwithparadoxicalhdlcholesteroldecreaseinresponsetofenofibricacidtherapys AT robertahegele rareapoa5promotervariantsassociatedwithparadoxicalhdlcholesteroldecreaseinresponsetofenofibricacidtherapys AT christiemballantyne rareapoa5promotervariantsassociatedwithparadoxicalhdlcholesteroldecreaseinresponsetofenofibricacidtherapys |